Merck & Co. (MRK)
(Delayed Data from NYSE)
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:24 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.69 USD
+0.60 (0.53%)
Updated Sep 27, 2024 04:00 PM ET
After-Market: $113.60 -0.09 (-0.08%) 7:24 PM ET
4-Sell of 5 4
C Value C Growth B Momentum B VGM
Zacks News
Nektar (NKTR) Stock Up 3% on Q3 Earnings and Revenue Beat
by Zacks Equity Research
Nektar (NKTR) reports encouraging third-quarter 2020 results. Enrollment in clinical studies back on track.
Iovance (IOVA) Q3 Earnings Beat Estimates, Pipeline in Focus
by Zacks Equity Research
Iovance's (IOVA) third-quarter earnings beat estimates. The company is progressing well with development of its lead pipeline candidate.
Exelixis' (EXEL) Q3 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Exelixis (EXEL) posts a wider-than-expected loss for the third quarter but beats on revenues.
Bristol-Myers (BMY) Q3 Earnings Beat, '20 EPS View Raised
by Zacks Equity Research
Bristol-Myers (BMY) beats on earnings and sales in the third quarter on strength of Revlimid and Eliquis.
AstraZeneca (AZN) Q3 Earnings Miss Estimates, Sales Beat
by Zacks Equity Research
AstraZeneca (AZN) lags Q3 earnings estimates and surpasses the same for sales. It maintains its financial outlook for the year.
Corcept (CORT) Misses on Q3 Earnings, Tightens 2020 Sales View
by Zacks Equity Research
Corcept's (CORT) earnings and revenues fall shy of estimates in the third quarter of 2020. The company tapers its revenue guidance for the year. Shares fall in after-hours trading.
Esperion (ESPR) Q3 Earnings Top, Coronavirus Woes Linger
by Zacks Equity Research
Esperion Therapeutics (ESPR) reports strong third-quarter results, beating estimates for earnings and sales. However, stock declines on COVID-19 related uncertainties.
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Eli Lilly, Merck, Pfizer, Novartis, AstraZeneca and J&J
What's in Store for AstraZeneca (AZN) This Earnings Season?
by Zacks Equity Research
AstraZeneca's (AZN) third-quarter results are expected to reflect the impact of new drug sales.
Moderna (MRNA) Q3 Earnings Lag Estimates, Pipeline Advances
by Zacks Equity Research
Moderna (MRNA) reports wider-than-expected third-quarter loss. However, revenues beat estimates significantly. Shares up presumably on encouraging pipeline progress and rising cash resources.
Seagens (SGEN) Q3 Earnings Rise Y/Y, Adcetris Sales View Cut
by Zacks Equity Research
Seagen's (SGEN) bottom line grows year over year in Q3 while revenues beat estimates. The company lowers the sales guidance for its lead product Adcetris.
Pharma Stock Roundup: Q3 Earnings, Resumption of AZN/JNJ Coronavirus Vaccine Study
by Kinjel Shah
Eli Lilly (LLY), Merck (MRK), Pfizer (PFE), Novartis (NVS) and others release Q3 results
Worried About Dow's Massive Crash? ETF & Stocks to Play
by Sanghamitra Saha
Rising fears of a second wave of lockdown globally sent Wall Street crashing on Wednesday with the Dow Jones being one of the worst hurt.
Exelixis' (EXEL) Applications for Cabometyx-Opdivo Combo Accepted (Revised)
by Zacks Equity Research
Exelixis' (EXEL) applications for Cabometyx in combination with Opdivo for the treatment of RCC has been accepted by the FDA.
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Merck & Co., Bristol-Myers Squibb and Amgen
Wall Street Opens Green on Strong Economic Data
by Zacks Equity Research
Wall Street Opens Green on Strong Economic Data.
Markets Buoy on Durable Goods, Q3 Earnings: MRK, CAT, MMM, AMD
by Mark Vickery
Markets are up in early trading today, even though a congressional stimulus package looks kaput.
Merck (MRK) Beats on Q3 Earnings & Sales, Updates Guidance
by Zacks Equity Research
Merck (MRK) increases earnings guidance while tightening sales outlook for the year. Shares up in pre-market trading.
Merck (MRK) Beats Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 20.83% and 2.42%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Big Techs to Report Earnings Results This Week
by Zacks Equity Research
Big Techs to Report Earnings Results This Week.
Europe Covid Cases Dampen World Markets
by Mark Vickery
Covid cases here in the U.S. are also troubling: we have a record high new cases per day for three days in a row.
Will AbbVie (ABBV) Q3 Earnings Recover From Coronavirus Woes?
by Zacks Equity Research
Investors will focus on any recovery in AbbVie's (ABBV) sales amid the coronavirus pandemic when it reports third-quarter results.
Will Pfizer's (PFE) Oncology Drugs Drive Its Q3 Earnings?
by Zacks Equity Research
In Pfizer's (PFE) Biopharma unit, oncology sales are likely to have risen in the third quarter, while in non-oncology, Eliquis alliance revenues are likely to have supported the top line.
Healthcare to Post Solid Q3 Earnings Growth: ETFs in Focus
by Sweta Killa
The healthcare is expected to witness substantial earnings growth of 5.1% in the third quarter, representing the second strongest sector this earnings season.
Novartis (NVS) Gets Orphan Drug Tag for Huntington's Disease Drug
by Zacks Equity Research
Novartis (NVS) gets orphan drug designation for branaplam (LMI070) in Huntington's disease.